REDMOND,
Wash., March 18, 2024 /PRNewswire/
-- Microsoft Corp. is expanding its collaboration with NVIDIA
to bring the power of generative AI, the cloud and accelerated
computing to healthcare and life sciences organizations. The
collaboration will bring together the global scale, security and
advanced computing capabilities of Microsoft Azure with
NVIDIA DGX Cloud and the NVIDIA Clara suite of computing
platforms, software and services to help healthcare and life
sciences organizations accelerate innovation and improve patient
care. Harnessing the immense power of the cloud, cutting-edge AI
and advanced computing capabilities, the collaboration aims to
accelerate clinical research and drug discovery, enhance medical
image-based diagnostic technology, and increase access to precision
medicine.
"Microsoft is building on its longstanding collaboration with
NVIDIA to empower the healthcare and life sciences industry with
the power of Azure and generative AI, helping unlock new horizons
for clinical research, drug discovery and patient care worldwide,"
said Peter Durlach, corporate vice
president, Health & Life Sciences, Microsoft. "Through this
collaboration, we aim to help the industry unlock breakthroughs in
healthcare, making care more precise, accessible and effective to
deliver a meaningful difference in the lives of patients
globally."
"The convergence of AI, cloud computing and healthcare is set to
transform patient care," said Kimberly
Powell, vice president of healthcare, NVIDIA. "Our
collaboration with Microsoft will help unlock new possibilities and
drive meaningful impact for patients worldwide."
The expanded collaboration will extend opportunities for
healthcare providers, pharmaceutical and biotechnology companies,
and medical device developers to innovate rapidly across clinical
research, drug discovery and care delivery with improved efficiency
and effectiveness.
Faster drug discovery with NVIDIA BioNeMo on NVIDIA DGX
Cloud, hosted on Microsoft Azure
Hosted on NVIDIA DGX Cloud on Azure, NVIDIA BioNeMo offers the
quickest path to AI model development and deployment, accelerating
the journey to AI-powered drug discovery. BioNeMo is a generative
AI platform for drug discovery that simplifies and accelerates the
training of models on proprietary data and scales the deployment of
models for drug discovery applications. By analyzing vast datasets
with unprecedented speed and precision, it can help scientists
identify potential drug candidates more efficiently. The
implications are profound: faster access to lifesaving therapies
for patients worldwide.
Enhancing clinical research and care delivery with
imaging-based AI diagnostic technology leveraging Microsoft Azure,
NVIDIA MONAI and the Nuance Precision Imaging Network
The combination of the power of Azure, NVIDIA MONAI (Medical
Open Network for AI), and the Nuance Precision Imaging Network
(PIN) enables safe and effective development, validation,
deployment and evaluation of medical imaging AI models at scale.
With the combined offering, developers can build highly performant
medical imaging AI models, healthcare providers can deploy a single
PIN platform for running a wide array of third-party AI models
integrated into clinical workflows, and clinical researchers can
accelerate drug discovery. For example, Mass General Brigham AI
leveraged MONAI and PIN in the aftermath of COVID-19 to support a
federated approach to build models capable of assessing lung
function and predicting oxygen requirements for symptomatic
patients.
Additionally, Flywheel is providing a highly optimized imaging
data management application for data scientists, integrated with
MONAI and built on Azure AI, that significantly improves the way
medical imaging data are curated and greatly reduces the time
needed for research data preparation and medical AI model
training.
Flywheel, NVIDIA and researchers at the University of Wisconsin School of Medicine and
Public Health are also working together to revolutionize medical
imaging research through AI technology. The collaboration combines
the medical research insights of the UW–Madison team, Flywheel's
imaging data platform and NVIDIA MONAI microservices, powered by
Azure, to enable automated anatomical study classifications. The
initiative has the potential to revolutionize medical imaging
curation and greatly reduce the time needed for research data
preparation, representing a significant leap toward enabling
AI-driven medical breakthroughs.
"Our team at the UW School of Medicine and Public Health is
focused on applying advanced technology to boost our research
efforts and make it easier for our study teams to access
large-scale datasets," said John Garrett, Ph.D., assistant
professor of radiology and medical physics and director of imaging
informatics at UW–Madison. "Through this initiative, we're able to
harness advanced methods and take advantage of Flywheel and
NVIDIA's platforms and tools to scale our data curation process,
allowing us to spend more time on research projects and training AI
models."
Accelerating genomics analysis with the SOPHiA
DDMTM Platform on Azure powered by NVIDIA
Parabricks
Microsoft, NVIDIA and SOPHiA GENETICS are collaborating to
leverage combined expertise in technology and genomics to develop a
streamlined, scalable and comprehensive whole-genome analytical
solution. As part of this collaboration, the SOPHiA DDM
Software-as-a-Service platform, hosted on Azure, will be powered by
NVIDIA Parabricks for SOPHiA DDM's whole genome application.
Parabricks is a scalable genomics analysis software suite that
leverages full-stack accelerated computing to process whole genomes
in minutes. Compatible with all leading sequencing instruments,
Parabricks supports diverse bioinformatics workflows and integrates
AI for accuracy and customization. SOPHiA GENETICS will also
use powerful NVIDIA GPUs on Azure to process computationally heavy
workloads, providing a scalable and efficient solution.
"At SOPHiA GENETICS, we offer a universal cloud-based platform —
the SOPHiA DDM™ platform — that enables healthcare institutions to
get quick, robust and actionable insights from their data. Our
technology analyzes genomic data, alongside other modalities, to
provide collective intelligence for institutions worldwide to
support discoveries, treatment decisions and drug development
efforts, benefiting patients with cancer and rare inherited genetic
disorders. By leveraging the capabilities of Azure and NVIDIA
technology, we will be able to scale our top analytical
performance, short turnaround time and cost-effective solutions to
encompass the whole genome, further expanding our ability to
benefit our customers and their patients," said Abhimanyu Verma, chief technology officer,
SOPHiA GENETICS.
Azure AI: Democratizing AI for healthcare
professionals
Microsoft is collaborating with NVIDIA to make a future suite of
NVIDIA healthcare microservices available on Azure AI for optimized
inference and fine-tuning. Once available, researchers, clinicians
and developers can explore these state-of-the-art models and deploy
them as endpoints in the Azure AI Model Catalog. Azure AI
democratizes AI adoption for users in healthcare, from radiologists
fine-tuning an AI algorithm to geneticists deciphering complex
variants, while driving innovation and redefining patient care
through collaboration across disciplines.
Microsoft aims to propel healthcare and life sciences into an
exciting new era of medicine, helping unlock transformative
possibilities for patients worldwide. The combination of the global
scale, security and advanced computing capabilities of
Microsoft Azure with NVIDIA DGX Cloud and the NVIDIA Clara suite is
set to accelerate advances in clinical research, drug discovery and
care delivery.
Microsoft (Nasdaq "MSFT" @microsoft) enables digital
transformation for the era of an intelligent cloud and an
intelligent edge. Its mission is to empower every person and every
organization on the planet to achieve more.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/microsoft-announces-collaboration-with-nvidia-to-accelerate-healthcare-and-life-sciences-innovation-with-advanced-cloud-ai-and-accelerated-computing-capabilities-302092054.html
SOURCE Microsoft Corp.